Minhai COVID-19 vaccine (Chinese: 康泰民海新冠疫苗), trademarked as KCONVAC (Chinese: 可维克; pinyin: Kěwéikè), is a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Other names | KCONVAC (Chinese: 可维克; pinyin: Kěwéikè) |
| Routes of administration | Intramuscular |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
Clinical trials
editIn October 2020, KCONVAC started phase I clinical trials with 180 participants in China.[1] Later, KCONVAC started phase II trials with 1,000 participants in China.[2]
In May 2021, KCONVAC started phase III trials for global trials with 28,000 participants.[3]
Children and adolescents trials
editIn August 2021, KCONVAC started phase I trials with 84 participants in China.[4]
In September, KCONVAC started phase II trials with 480 participants in China.[5]
Authorizations
edit
Full authorization
Emergency authorization
Allowed for travel | ||
On 14 May 2021, the vaccine became the fourth inactivated Chinese Vaccine to be authorised for emergency use.[6]
References
edit- ^ Clinical trial number NCT04756323 for "A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19) " at ClinicalTrials.gov
- ^ Clinical trial number NCT04758273 for "A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)" at ClinicalTrials.gov
- ^ Clinical trial number NCT04852705 for "A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)" at ClinicalTrials.gov
- ^ Clinical trial number NCT05003479 for "A Phase I Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)" at ClinicalTrials.gov
- ^ Clinical trial number NCT05003466 for "A Phase II Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)" at ClinicalTrials.gov
- ^ "Kangtai Biological's COVID-19 vaccine gets emergency use approval in China". Reuters. 14 May 2021. Retrieved 20 May 2021.
.svg){kind=small}
.png){kind=small} | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |